PTAFR and ovarian carcinoma: Our previous study reported that the PAFR ligand PAF can activate phospho-EGFR and induce proliferation and invasion in ovarian cancer, and the results of the present study show that the PAFR antagonist WEB2086 can inhibit EGFR activation.